Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Retaining HIV-infected patients in care: Where are we? Where do we go from here?

Horstmann E, Brown J, Islam F, Buck J, Agins BD.

Clin Infect Dis. 2010 Mar 1;50(5):752-61. doi: 10.1086/649933. Review.

PMID:
20121413
2.

Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities.

Nachega JB, Mills EJ, Schechter M.

Curr Opin HIV AIDS. 2010 Jan;5(1):70-7. doi: 10.1097/COH.0b013e328333ad61. Review.

PMID:
20046150
3.

Characteristics of and outcomes in HIV-infected patients who return to care after loss to follow-up.

Ndiaye B, Ould-Kaci K, Salleron J, Bataille P, Bonnevie F, Cochonat K, Fontier C, Guerroumi H, Yazdanpanah Y.

AIDS. 2009 Aug 24;23(13):1786-9. doi: 10.1097/QAD.0b013e32832e3469.

PMID:
19531927
4.

Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study.

Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD.

AIDS Behav. 2010 Aug;14(4):778-84. doi: 10.1007/s10461-009-9533-2. Epub 2009 Mar 13.

5.

Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116).

Marcellin F, Boyer S, Protopopescu C, Dia A, Ongolo-Zogo P, Koulla-Shiro S, Abega SC, Abé C, Moatti JP, Spire B, Carrieri MP; EVAL Study Group.

Trop Med Int Health. 2008 Dec;13(12):1470-8. doi: 10.1111/j.1365-3156.2008.02170.x. Epub 2008 Nov 5.

6.

The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.

Bennett DE, Bertagnolio S, Sutherland D, Gilks CF.

Antivir Ther. 2008;13 Suppl 2:1-13.

PMID:
18578063
7.

Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment.

Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF.

Antivir Ther. 2008;13 Suppl 2:25-36.

PMID:
18575189
8.

World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.

Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D.

Antivir Ther. 2008;13 Suppl 2:15-23.

PMID:
18575188
9.

Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy.

Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, Frank I, Maartens G, Nachega JB.

PLoS Med. 2008 May 20;5(5):e109. doi: 10.1371/journal.pmed.0050109.

10.
11.

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.

Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR.

AIDS. 2007 May 11;21(8):965-71.

PMID:
17457090
12.

Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Côte d'Ivoire.

Eholié SP, Tanon A, Polneau S, Ouiminga M, Djadji A, Kangah-Koffi C, Diakité N, Anglaret X, Kakou A, Bissagnené E.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):355-8.

PMID:
17438479
13.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
14.

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.

Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, Wood E, Dong WW, Montaner JS, Harrigan PR.

PLoS Med. 2006 Sep;3(9):e356.

15.

Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV.

Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):96-101.

PMID:
16123689
16.

Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.

van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, de Baar MP, Schuurman R, Burger DM, Zijlstra EE.

Trop Med Int Health. 2005 May;10(5):464-70.

17.

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.

Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouzé B, Verdon R.

Clin Infect Dis. 2004 May 1;38(9):1311-6. Epub 2004 Apr 14.

PMID:
15127346
18.

Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries.

Vergne L, Malonga-Mouellet G, Mistoul I, Mavoungou R, Mansaray H, Peeters M, Delaporte E.

J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):165-8.

PMID:
11832686
19.

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F.

JAMA. 2000 Jan 12;283(2):205-11. Erratum in: JAMA 2000 Sep 27;284(12):1518.

PMID:
10634336
20.

Supplemental Content

Support Center